- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Briana and Qualia finalize CAD deal
Briana Bio-Tech of Edmonton, Alberta, and Qualia Computing of Beavercreek, OH, have completed an agreement in which Qualia has granted licensing rights to Briana for its Second Look computer-aided diagnosis mammography workstation (SCAN 6/25/97). Under
Briana Bio-Tech of Edmonton, Alberta, and Qualia Computing of Beavercreek, OH, have completed an agreement in which Qualia has granted licensing rights to Briana for its Second Look computer-aided diagnosis mammography workstation (SCAN 6/25/97). Under the agreement, Briana has paid US$800,000 to Qualia and has committed to pay an additional $3.4 million in installments over the next 18 months in exchange for exclusive worldwide rights to Second Look and a 30% equity stake in Qualia. Qualia will also receive royalties on sales of Second Look systems.
Briana plans to show a commercial prototype of Second Look at the upcoming Radiological Society of North America meeting, and begin shipments to European and Asian markets in the second half of 1998.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
